This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neos Therapeutics (NEOS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ArQule (ARQL) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
ArQule (ARQL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
Neos Therapeutics Enters Oversold Territory
by Zacks Equity Research
Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Neos Therapeutics (NEOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Neos Therapeutics (NEOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Neos Therapeutics (NEOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Neos Therapeutics (NEOS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Neos Therapeutics (NEOS) stock based on the movements in the options market lately.
Teva Stock Rises on Patent Settlement With Neos Therapeutics
by Zacks Equity Research
Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.
Company News For Dec 27, 2018
by Zacks Equity Research
Companies In The News Are: TEVA,NEOS,JD,EXPE,INTC,MAR
Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -7.50% and -15.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Neos Therapeutics (NEOS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -20.93% and -4.51%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
by Zacks Equity Research
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
5 of the Best Stocks Under $10 for 2017
by Ryan McQueeney
Today we've highlighted five stocks that are currently trading for under $10 per share. These stocks are also showing signs for solid growth throughout 2017, and all of them currently hold a Zacks Rank #1 (Strong Buy).
What Falling Estimates & Price Mean for Cardiome (CRME)
by Zacks Equity Research
Cardiome (CRME) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Ironwood Pharma's Combination Gout Drug Gets FDA Approval
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.
Can The Uptrend Continue for Neos Therapeutics (NEOS)?
by Zacks Equity Research
Investors certainly have to be happy with Neos Therapeutics, Inc. (NEOS) and its short term performance
Why Endo International (ENDP) Could Be Positioned for a Slump
by Zacks Equity Research
One stock that you may want to consider dropping is Endo International plc (ENDP), which has witnessed a significant price decline in the past four weeks.
Genocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher
by Zacks Equity Research
Genocea Biosciences, Inc. (GNCA) shares rose almost 12% in the last trading session.
Should You Get Rid of Valeant Pharmaceuticals International (VRX) Now?
by Zacks Equity Research
Valeant Pharmaceuticals International (VRX) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
Zacks.com featured highlights: Neos Therapeutics, Fire Eye, Amaya, Range Resources and Avinger
by Zacks Equity Research
Zacks.com featured highlights: Neos Therapeutics, Fire Eye, Amaya, Range Resources and Avinger
New Strong Buy Stocks for March 2nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday